^(18)F-FDG PET/CT联合血清FGFR4,CA19-9对非小细胞肺癌患者新辅助化疗疗效的评估价值  

The Evaluation Value of ^(18)F-FDG PET/CT Combined with Serum FGFR4 and CA19-9 for the Efficacy of Neoadjuvant Chemotherapy in Non-small Cell Lung Carcinoma Patients

作　　者：宋晏 付伟 张洁 SONG Yan;FU Wei;ZHANG Jie(Department of Nuclear Medicine,Shaanxi Hanzhong 3201 Hospital,Hanzhong 723000,China)

机构地区：[1]陕西汉中三二〇一医院核医学科,陕西汉中723000

出　　处：《标记免疫分析与临床》2025年第3期568-573,共6页Labeled Immunoassays and Clinical Medicine

摘　　要：目的探究^(18)F-FDG PET/CT联合血清成纤维生长因子受体4(FGFR4),糖类抗原19-9(CA19-9)对非小细胞肺癌(NSCLC)患者新辅助化疗疗效的评估价值。方法选择2021年9月至2023年7月期间在本院诊治的120例NSCLC患者,并进行新辅助化疗,根据治疗效果将患者分为无效组(28例)和有效组(92例)。对患者进行PET/CT检查,记录肿瘤标准摄取值(SUV)的最大值(SUV max),以40%SUV max为阈值获取SUV均值(SUV mean)和肿瘤代谢体积(MTV),并计算总糖酵解(TLG);ELISA检测FGFR4、CA19-9水平;肺癌患者生活质量测定量表(FACT-L)对患者生活质量进行评价。多因素Logistic回归分析新辅助化疗疗效的影响因素,Pearson和Spearman相关性分析各影响因素与FACT-L评分的相关性,ROC曲线分析MTV联合血清FGFR4,CA19-9对NSCLC患者新辅助化疗疗效的诊断价值,Z检验比较曲线下面积(AUC)的差异。结果有效组SUV mean、MTV、TLG、FGFR4、CA19-9较低,而中分化人数所占组内比例及FACT-L评分较高(P<0.05);分化程度、FACT-L评分高为NSCLC患者新辅助化疗无效的独立保护因素,MTV、FGFR4、CA19-9高为NSCLC患者新辅助化疗无效的独立危险因素(P<0.05);患者肿瘤分化程度、MTV、FGFR4、CA19-9与FACT-L评分呈负相关(P<0.05);MTV联合血清FGFR4,CA19-9诊断NSCLC患者新辅助化疗疗效的AUC为0.815、0.841、0.807,联合诊断的AUC为0.952,优于各自单独诊断(P<0.05)。结论新辅助化疗有效的NSCLC患者MTV、FGFR4、CA19-9较低,生活质量升高,3者联合诊断新辅助化疗有效具有较高的价值,可为临床诊断提供理论基础。Objective To explore the evaluation value of ^(18)F-FDG PET/CT combined with serum fibroblast growth factor receptor 4(FGFR4)and carbohydrate antigen 199(CA19-9)for the efficacy of neoadjuvant chemotherapy in non-small cell lung carcinoma(NSCLC)patients.Methods This study selected 120 NSCLC patients who were treated in our hospital between September,2021 and July,2023,and received neoadjuvant chemotherapy.According to the treatment effect,these patients were divided into an ineffective group(28 cases)and an effective group(92 cases).PET/CT examination was performed among patients.The maximum value of tumor standardized uptake value(SUV max)was recorded.Using 40%SUV max as the threshold,SUV mean and metabolic tumor volume(MTV)were obtained,and total lesion glycolysis(TLG)was calculated;The levels of FGFR4 and CA19-9 were measured by ELISA.The Functional Assessment of Cancer Therapy-Lung cancer(FACT-L)was applied to evaluate the quality of life of all patients.Multivariate logistic regression was applied to identify the influencing factors of neoadjuvant chemotherapy efficacy.Pearson and Spearman correlation methods were applied to analyze the correlation between various influencing factors and FACT-L scores.ROC curve was drawn to evaluate the diagnostic value of MTV combined with serum FGFR4 and CA19-9 in the efficacy of neoadjuvant chemotherapy in NSCLC patients.Z-test was applied to identify the differences in area under the ROC curve(AUC).Results The effective group had significantly lower SUV mean,MTV,TLG,FGFR4,and CA19-9,while significantly higher proportion of moderately differentiated individuals within the group and FACT-L score(P<0.05).The degree of differentiation and high FACT-L score were independent protective factors for the ineffectiveness of neoadjuvant chemotherapy in NSCLC patients,while high MTV,FGFR4,and CA19-9 were independent risk factors for the ineffectiveness of neoadjuvant chemotherapy in NSCLC patients(P<0.05).The degree of tumor differentiation,MTV,FGFR4,CA19-9,and FACT-L score of patie

关 键 词：非小细胞肺癌 ^(18)F-FDG PET/CT 成纤维生长因子受体4 糖类抗原19-9 新辅助化疗 疗效评估 

分 类 号：R734.2[医药卫生—肿瘤]